It was FDA-approved in adults with relapsed/refractory FLT3-mutated AML after demonstrating a tolerable safety profile with a 20–30% CR rate and significantly prolonged survival when given as monotherapy [85, 86]. This evidence concerns the gene FLT3 and acute myeloid leukemia.